FBR Capital analyst Christopher James reiterated his Outperform rating and $10 price target on Anavex Life Sciences (NASDAQ: AVXL) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE